ClinicalTrials.gg
CompletedNCT00773695Updated Jan 9, 2023

A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

A Phase 2 interventional study of Aromatase Inhibitor and Bevacizumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 3 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-09.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 349 studies testing Aromatase inhibitors in Breast Neoplasms — 53 open to participants now, 81 under way, 22 of them phase 3. A drug class: Aromatase inhibitors · Breast Neoplasms.

Enrollment
140th of 341
150 · median 112
Started
2008
with 19 others
Phase 2
166 of 349
36 open now
Registered
128th of 349
by date

Among the 349 studies testing Aromatase inhibitors in Breast Neoplasms, this one is the 140th largest by enrollment of the 341 interventional ones that give a count, is one of 20 that started in 2008, is one of 166 in phase 2, and was the 128th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

53 of the 349 studies testing Aromatase inhibitors in Breast Neoplasms are open now, in 12 countries. Recruiting first, the newest first:

48 more — sign in →

By country, each count listing its studies:

All 53 open studies →

About Aromatase inhibitors

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 349 studies testing Aromatase inhibitors in Breast Neoplasms, or all of them as a file.
02

Study summary

This study will evaluate the effect of bevacizumab in combination with chemotherapy or endocrine therapy, as preoperative treatment, in participants with HER2 negative breast cancer. Participants will be randomized to receive either chemotherapy (FEC100: Epirubicine 100 milligrams per square meter [mg/m\^2], 5-fluorouracil 600 mg/m\^2, and cyclophosphamide 600 mg/m\^2] for 12 weeks followed by taxane (paclitaxel/docetaxel) for 12 weeks or endocrine therapy (an aromatase inhibitor] daily for 24 weeks) with or without bevacizumab (15 milligrams per kilogram [mg/kg] as intravenous [IV] infusion every 3 weeks up 24 weeks).

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed, -negative, men or pre- or women with primary operable adenocarcinoma of the breast, greater than or equal to (>=) 2.5 centimeters (cm) in size
  • (ECOG)/world health organization (WHO) performance status less than or equal to (\</=) 2
  • Normal baseline cardiac function ( [LVEF])

Exclusion criteria

Exclusion Criteria:

  • Stage IV () disease
  • Previous treatment for localized breast cancer less than (\<) 24 months from diagnosis of present breast cancer
  • Other previous or current cancer except for basal cell cancer or in situ cervical cancer
  • Current or recent use of aspirin (greater than [>] 325 milligrams per day)
  • cardiovascular disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
150 participants (actual)

Study arms

  • Active comparator
    Chemotherapy

    Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks.

    Drug: Epirubicine · Drug: 5-Fluorouracil (5FU) · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Docetaxel

  • Experimental
    Chemotherapy and Bevacizumab

    Participants will receive epirubicine, 5-fluorouracil, and cyclophosphamide (FEC 100) for 12 weeks followed by taxane therapy (paclitaxel or docetaxel) for next 12 weeks. Participants will also receive concurrent treatment with bevacizumab every 3 weeks for 24 weeks.

    Drug: Bevacizumab · Drug: Epirubicine · Drug: 5-Fluorouracil (5FU) · Drug: Cyclophosphamide · Drug: Paclitaxel · Drug: Docetaxel

  • Active comparator
    Endocrine Therapy

    Participants will receive aromatase inhibitor therapy at discretion of the investigator for a period of 24 weeks.

    Drug: Aromatase Inhibitor

  • Experimental
    Endocrine Therapy and Bevacizumab

    Participants will receive aromatase inhibitor therapy at discretion of the investigator and concurrent treatment with bevacizumab for a period of 24 weeks.

    Drug: Aromatase Inhibitor · Drug: Bevacizumab

Interventions

  • Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.

  • Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.

    Also known as: Avastin

  • Participants will receive epirubicine at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

  • Participants will receive 5FU at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

  • Participants will receive cyclophosphamide at a dose of 600 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

  • Participants will receive paclitaxel at a dose of 80 mg/m\^2 as IV infusion every week for 12 weeks.

  • Participants will receive docetaxel at a dose of 100 mg/m\^2 as IV infusion every 3 weeks for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Messenger Ribonucleic Acid (mRNA) Markers of Pathological Complete Response, as Assessed by Magnetic Resonance Imaging (MRI)

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

Secondary outcomes

  1. Percentage of Participants With Objective Pathological Complete Response, as Assessed by Clinical Assessment

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  2. Percentage of Participants With Type of Surgery

    Percentage of participants with different surgery types (for example, Mastectomy, Tumorectomy/Breast conserving therapy (BCT), and Tumorectomy followed by mastectomy) will be reported.

    Time frame: At Surgery (Between Weeks 24 and 25)

  3. Percentage of Participants With Axillary Lymph Node Dissection Performed

    Time frame: At Surgery (Between Weeks 24 and 25)

  4. Pathological Tumor Size, as Assessed by Histopathological Examination

    Time frame: At Surgery (Between Weeks 24 and 25)

  5. Percentage of Participants With Presence of Tumor Cells Close to Resection Margin

    Time frame: At Surgery (Between Weeks 24 and 25)

  6. Percentage of Participants With Tumor Deposit in Other Body Parts

    Time frame: At Surgery (Between Weeks 24 and 25)

  7. Tumor Free Resection Margin

    Time frame: At Surgery (Between Weeks 24 and 25)

  8. Pathological Tumor Size as Measure Using Caliper

    Time frame: Cycles 1 to 10 (cycle length=21 days), and Week 25

  9. Pathological Tumor Size as Measure Using MRI

    Time frame: Baseline, Weeks 12 and 25

  10. Pathological Tumor Size as Measure Using Mamography

    Time frame: Baseline, Weeks 12 and 25

  11. Pathological Breast Tumor Size as Measure Using Ultrasound

    Time frame: Baseline, Weeks 12 and 25

  12. Pathological Axilla Tumor Size as Measure Using Ultrasound

    Time frame: Baseline, Weeks 12 and 25

  13. Percentage of Participants With Eastern Cooperative Oncology Group (ECOG) Performance Status

    Time frame: Screening, Cycles 1 to 10 (cycle length=21 days), and Week 25

  14. Percentage of Participants With Lymph Node Involvement

    Time frame: Cycles 1 to 10 (cycle length=21 days), and Week 25

  15. Percentage of Participants With Objective Tumor Response, as Assessed Using Response Evaluation Criteria in Solid Tumors (RECIST)

    Time frame: Weeks 12 and 25

  16. Percentage of Participants With New Lesions

    Time frame: Weeks 12 and 25

  17. Percentage of Participants With Molecular Changes in Protein Kinase Expression

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  18. Percentage of Participants With Molecular Changes in Messenger Ribonucleic Acid (mRNA)/microRNA(miRNA)

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  19. Percentage of Participants With Molecular Changes in Protein Expression

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  20. Percentage of Participants With Single Nucleotide Polymorphism (SNP) Profiles Predicting Treatment Response

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  21. Percentage of Participants With Treatment-Induced Changes in Tumor Cells as Determined by Number of Disseminated Tumor Cells in Bone Marrow

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

  22. Percentage of Participants With Treatment-Induced Changes in Tumor Cells as Determined by Number of Circulating Tumor Cells in Peripheral Blood

    Time frame: Baseline up to end of study treatment (approximately 24 weeks)

07

Study locations

3 sites
  • The Norvegian Radium Hospital Montebello; Dept of Oncology
    Oslo, 0379, Norway
  • Ullevael Sykehus; Dept of Oncology
    Oslo, 0407, Norway
  • St. Olavs Hospital; Kreftavdelingen
    Trondheim, 7000, Norway
08

References and documents

Publications

  • Hoglander EK, Nord S, Wedge DC, Lingjaerde OC, Silwal-Pandit L, Gythfeldt HV, Vollan HKM, Fleischer T, Krohn M, Schlitchting E, Borgen E, Garred O, Holmen MM, Wist E, Naume B, Van Loo P, Borresen-Dale AL, Engebraaten O, Kristensen V. Time series analysis of neoadjuvant chemotherapy and bevacizumab-treated breast carcinomas reveals a systemic shift in genomic aberrations. Genome Med. 2018 Nov 29;10(1):92. doi: 10.1186/s13073-018-0601-y. PubMed 30497530 ↗
  • Reinertsen KV, Engebraaten O, Loge JH, Cvancarova M, Naume B, Wist E, Edvardsen H, Wille E, Bjoro T, Kiserud CE. Fatigue During and After Breast Cancer Therapy-A Prospective Study. J Pain Symptom Manage. 2017 Mar;53(3):551-560. doi: 10.1016/j.jpainsymman.2016.09.011. Epub 2016 Dec 29. PubMed 28042070 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2008 to primary completion in Nov 2022, 168 months.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 168 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2008
First posted
Oct 16, 2008
StartActual
Nov 7, 2008
Primary completionActual
Nov 9, 2022
CompletionActual
Nov 9, 2022
Last update
Jan 9, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 9, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00773695
Lead sponsor
Hoffmann-La Roche
Collaborators
Norwegian Radium Hospital
Responsible party
Sponsor
First posted
Oct 16, 2008
Start date
Nov 7, 2008
Primary completion
Nov 9, 2022
Completion
Nov 9, 2022
Last update
Jan 9, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Aromatase inhibitors · Bevacizumab · Epirubicin · Fluorouracil · Cyclophosphamide · Paclitaxel · Docetaxel

Start the discussion